{
  "id": "5a722ccd2dc08e987e000003",
  "type": "summary",
  "question": "What is the mechanism of action of Tezepelumab?",
  "ideal_answer": "Tezepelumab is human monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28583618",
    "http://www.ncbi.nlm.nih.gov/pubmed/28368013",
    "http://www.ncbi.nlm.nih.gov/pubmed/28877011"
  ],
  "snippets": [
    {
      "text": "These include monoclonal antibodies against IL-5 or IL-5 receptor alpha (mepolizumab, reslizumab, and benralizumab), IL-13 (lebrikizumab and tralokinumab), IL-4 receptor alpha (dupilumab), IgE (omalizumab), and anti-thymic stromal lymphopoietin (tezepelumab) and small molecule therapies such as prostaglandin D2blockers (fevipiprant and timapiprant). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28583618",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We further show that the monoclonal antibody Tezepelumab partly exploits these principles to neutralize TSLP activity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28368013",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose asthma remained uncontrolled despite treatment with long-acting beta-agonists and medium-to-high doses of inhaled glucocorticoids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose asthma remained uncontrolled despite treatment with long-acting beta-agonists and medium-to-high doses of inhaled glucocorticoids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose asthma remained uncontrolled despite treatment with long-acting beta-agonists and medium-to-high doses of inhaled glucocorticoids.<br><b>METHODS</b>: In this phase 2, randomized, double-blind, placebo-controlled trial, we compared subcutaneous tezepelumab at three dose levels with placebo over a 52-week treatment period.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These include monoclonal antibodies against IL-5 or IL-5 receptor alpha (mepolizumab, reslizumab, and benralizumab), IL-13 (lebrikizumab and tralokinumab), IL-4 receptor alpha (dupilumab), IgE (omalizumab), and anti-thymic stromal lymphopoietin (tezepelumab) and small molecule therapies such as prostaglandin D",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28583618",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin (TSLP), in patients whose asthma remained uncontrolled despite treatment with long-acting beta-agonists and medium-to-high doses of inhaled glucocorticoids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28877011",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These include monoclonal antibodies against IL-5 or IL-5 receptor alpha (mepolizumab, reslizumab, and benralizumab), IL-13 (lebrikizumab and tralokinumab), IL-4 receptor alpha (dupilumab), IgE (omalizumab), and anti-thymic stromal lymphopoietin (tezepelumab) and small molecule therapies such as prostaglandin D<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28583618",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These include monoclonal antibodies against IL-5 or IL-5 receptor alpha (mepolizumab, reslizumab, and benralizumab), IL-13 (lebrikizumab and tralokinumab), IL-4 receptor alpha (dupilumab), IgE (omalizumab), and anti-thymic stromal lymphopoietin (tezepelumab) and small molecule therapies such as prostaglandin D blockers (fevipiprant and timapiprant).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28583618",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}